公司简介
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ...
关联新闻
- US FDA approves Regeneron's drug for generalized myasthenia gravis
US FDA approves Regeneron's drug for generalized myasthenia gravis
- REGN Price Forecast: Rally Faces Resistance After 37% Advance
Regeneron shares face growing resistance after a 37% advance, with potential correction targets emerging while the intermediate- and long-term bullish trends remain intact.
- Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.
- Regeneron drug halves muscle loss in combination with Novo's semaglutide in trial
An experimental weight-loss drug being developed by Regeneron used in combination with Novo Nordisk's semaglutide reduced the loss of muscle mass by 50% compared with the loss seen with semaglutide al...
- US FDA approves Regeneron's rare bone disorder drug
The U.S. FDA on Wednesday approved Regeneron's experimental drug for a rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues.